奥扎格雷钠治疗急性脑血栓形成53例  

Clinical Efficacy and Safety of Sodium Ozagrel in Treating Acute Cerebral Thrombosis in 53 Cases

作　　者：吴成思[1] 封靖[1] 王雪梅[1] 

机构地区：[1]北京潞河医院神经内科,北京101149

出　　处：《中国药业》2013年第17期84-85,共2页China Pharmaceuticals

摘　　要：目的观察奥扎格雷钠治疗急性脑血栓形成的临床疗效和安全性。方法选取106例急性脑血栓形成患者,随机分为观察组和对照组,各53例。两组均给予常规治疗,观察组在常规治疗基础上给予奥扎格雷钠静脉滴注,对照组给予丹参粉针静脉滴注,14 d为1个疗程。比较两组的疗效及不良反应。结果观察组总有效率为92.45%,显著高于对照组的69.81%(P<0.05);两组的神经功能缺损评分治疗后均有显著改善,观察组的改善优于对照组(P<0.05);两组治疗过程中均未发生明显不良反应。结论奥扎格雷钠治疗急性脑血栓形成疗效显著、安全性好,具有较好的临床应用价值。Objective To observe the clinical efficacy and safety of sodium ozagrel in treating acute cerebral thrombosis. Methods One hundred and six patients with acute cerebral thrombosis were selected and randomly divided into the observation group and the control group, 53 cases in each group. On the basis of the conventional treatment, the observation group was given sodium ozagrel by intravenous drip, while the control group was given Danshen Powder Injection by intravenous drip, 14 days as a course of treatment. The efficacy and the adverse reactions after treatment were compared between the two groups. Results The effective rate was 92.45% in the observation group, which was significantly higher than 69.81% in the control group（P〈0.05）;the neurological deficit scores of the two groups were improved after treatment, but the improvement of the observation group was superior to the control group（ P 〈 0.05）;no significant adverse reactions occured during the treatment process of the two groups. Conclusion Sodium ozagrel has significant effect and good safey in acute cerebral thrombosis, and has good clinical application value.

关 键 词：急性脑血栓形成 奥扎格雷钠 血小板 

分 类 号：R969.4[医药卫生—药理学] R973.2[医药卫生—药学]